Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

C4 Therapeutics (CCCC) FCF Margin (2019 - 2026)

C4 Therapeutics has reported FCF Margin over the past 8 years, most recently at 487.35% for Q1 2026.

  • For Q1 2026, FCF Margin fell 2749.0% year-over-year to 487.35%; the TTM value through Mar 2026 reached 275.37%, down 7302.0%, while the annual FY2025 figure was 276.24%, 9263.0% down from the prior year.
  • FCF Margin for Q1 2026 was 487.35% at C4 Therapeutics, down from 201.13% in the prior quarter.
  • Over five years, FCF Margin peaked at 41.54% in Q2 2024 and troughed at 986.19% in Q4 2022.
  • A 5-year average of 426.36% and a median of 349.73% in 2022 define the central range for FCF Margin.
  • Biggest five-year swings in FCF Margin: tumbled -85780bps in 2022 and later soared 67258bps in 2024.
  • Year by year, FCF Margin stood at 986.19% in 2022, then soared by 30bps to 689.24% in 2023, then skyrocketed by 50bps to 346.3% in 2024, then soared by 42bps to 201.13% in 2025, then crashed by -142bps to 487.35% in 2026.
  • Business Quant data shows FCF Margin for CCCC at 487.35% in Q1 2026, 201.13% in Q4 2025, and 280.58% in Q3 2025.